Back to Interventions
Substance / Medication

Zanamivir

SNOMED 387010007UMLS C0216660

Overview

Active Ingredient
zanamivir
RxNorm CUI
69722
Labeler: GlaxoSmithKline LLCUpdated: 2023-10-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

5.2 11 [see Warnings and Precautions (), Description ()] RELENZA is contraindicated in patients with history of allergic reaction to any ingredient of RELENZA, including milk proteins.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Influenza

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
Heneghan Carl J, Onakpoya Igho, Thompson Matthew et al. · BMJ · 2014
PMID: 24811412Meta-AnalysisFull text (PMC)
Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review.
Jackson Rachel J, Cooper Katy L, Tappenden Paul et al. · J Infect · 2011
PMID: 20950645Meta-Analysis
Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
Tappenden P, Jackson R, Cooper K et al. · Health Technol Assess · 2009
PMID: 19215705Meta-Analysis
Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation.
Burls A, Clark W, Stewart T et al. · Health Technol Assess · 2002
PMID: 12065066Meta-Analysis
Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.
Kaiser L, Keene O N, Hammond J M et al. · Arch Intern Med · 2000
PMID: 11088083Meta-Analysis
Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial.
Li Min, Han Guang-Chao, Chen Yang et al. · Braz J Med Biol Res · 2020
PMID: 33263644RCTFull text (PMC)
Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial.
Coleman Brenda L, Fadel Shaza A, Drews Steven J et al. · Influenza Other Respir Viruses · 2015
PMID: 25557838RCTFull text (PMC)
The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.
Shida Y, Hara K, Nohda S et al. · J Clin Pharm Ther · 2013
PMID: 23489210RCT
Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.
Anekthananon T, Pukrittayakamee S, Pukritayakamee S et al. · J Antimicrob Chemother · 2013
PMID: 23143901RCTFull text (PMC)
An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.
Pukrittayakamee Sasithon, Jittamala Podjanee, Stepniewska Kasia et al. · Antimicrob Agents Chemother · 2011
PMID: 21690287RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Zanamivir (substance)
SNOMED CT
387010007
UMLS CUI
C0216660
RxNorm CUI
69722
Labeler
GlaxoSmithKline LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.